Detalles de la búsqueda
1.
Circulating tumor DNA as a potential marker of adjuvant chemotherapy benefit following surgery for localized pancreatic cancer.
Ann Oncol;
30(9): 1472-1478, 2019 09 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-31250894
2.
Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer.
Br J Cancer;
118(7): 947-954, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29515256
3.
Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pancreatic cancer given adjuvant chemotherapy.
Br J Cancer;
118(8): 1084-1088, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29523831
4.
The prognostic impact of consensus molecular subtypes (CMS) and its predictive effects for bevacizumab benefit in metastatic colorectal cancer: molecular analysis of the AGITG MAX clinical trial.
Ann Oncol;
29(11): 2240-2246, 2018 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30247524
5.
Hope, optimism and survival in a randomised trial of chemotherapy for metastatic colorectal cancer.
Support Care Cancer;
24(1): 401-408, 2016 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-26093975
6.
Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer.
Br J Cancer;
113(1): 37-45, 2015 Jun 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-26125443
7.
Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer.
Br J Cancer;
112(6): 963-70, 2015 Mar 17.
Artículo
en Inglés
| MEDLINE | ID: mdl-25742472
8.
The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials.
Br J Cancer;
111(6): 1122-31, 2014 Sep 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-25072258
9.
A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma.
Br J Cancer;
108(3): 503-11, 2013 Feb 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-23361051
10.
Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial.
Br J Cancer;
108(4): 771-4, 2013 Mar 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-23412099
11.
Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer.
Ann Oncol;
24(3): 710-8, 2013 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-23108953
12.
Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17.
Ann Oncol;
24(4): 953-60, 2013 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-23144444
13.
Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C.
Ann Oncol;
23(6): 1531-6, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-22039086
14.
A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy.
Invest New Drugs;
30(3): 1216-23, 2012 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-21594619
15.
Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab.
Ann Oncol;
22(8): 1834-8, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21273347
16.
Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial.
Br J Cancer;
102(3): 475-81, 2010 Feb 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-20068567
17.
TACTIC: a multicentre, open-label, single-arm phase II trial of panitumumab, cisplatin, and gemcitabine in biliary tract cancer.
Cancer Chemother Pharmacol;
78(2): 361-7, 2016 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-27335026
18.
The murine A33 antigen is expressed at two distinct sites during development, the ICM of the blastocyst and the intestinal epithelium.
Mech Dev;
98(1-2): 111-4, 2000 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-11044613
19.
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17.
Eur J Cancer;
51(11): 1405-14, 2015 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-25979833
20.
Systemic treatment of colorectal cancer.
Eur J Cancer;
38(7): 1000-15, 2002 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-11978525